Drugs / BMS-986416
last change Feb 2025 re-read 3 minutes ago

BMS-986416

Developed for
cancer
Investigated by
Bristol-Myers Squibb

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04943900 Aug 2021 → Feb 2025 cancer Bristol-Myers Squibb Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BMS-986416 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04943900 ↗